Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1049675

Dasatinib-induced nephrotic syndrome: a case of phenoconversion?


Rogulj, Inga Mandac; Matisic, Vid; Arsov, Borna; Boban, Luka; Juginovic, Alen; Molnar, Vilim; Primorac, Dragan
Dasatinib-induced nephrotic syndrome: a case of phenoconversion? // Croatian medical journal, 60 (2019), 3; 250-254 doi:10.3325/cmj.2019.60.250 (domaća recenzija, članak, znanstveni)


CROSBI ID: 1049675 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Dasatinib-induced nephrotic syndrome: a case of phenoconversion?

Autori
Rogulj, Inga Mandac ; Matisic, Vid ; Arsov, Borna ; Boban, Luka ; Juginovic, Alen ; Molnar, Vilim ; Primorac, Dragan

Izvornik
Croatian medical journal (0353-9504) 60 (2019), 3; 250-254

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
Antineoplastic Agents/adverse effects ; Antineoplastic Agents/metabolism ; Cytochrome P-450 CYP3A/genetics ; Dasatinib/adverse effects ; Dasatinib/metabolism ; Female Humans Imatinib Mesylate/therapeutic use ; Leukemia, Myelogenous, Chronic ; BCR-ABL Positive/drug therapy ; Nephrotic Syndrome/chemically induced ; Pharmacogenomic Testing Phenotype Protein Kinase Inhibitors/adverse effects ; Protein Kinase Inhibitors/metabolism ; Pyrimidines/therapeutic use ;

Sažetak
We present the case of a 33-year-old chronic myeloid leukemia (CML) female patient, in whom the occurrence of nephrotic syndrome, during the treatment with tyrosine kinase activity inhibitors (TKIs), was potentially influenced by transient phenoconversion. Seven years after the CML diagnosis in 2004 and complete response, the patient experienced pain in the mandible and extremities. After this, imatinib was replaced by nilotinib, but generalized maculopapular rash was presented and successfully treated with antihistamines. The therapy was then discontinued due to planned pregnancy, and the patient experienced a relapse of CML with BCR-ABL/ABL1 transcripts of 18.9%. Dasatinib was introduced, and CML was in remission. Two years later, urine protein levels (6.19 g/L) and erythrocyte sedimentation rate were elevated (ESR=90 mm/3.6 ks). The patient was diagnosed with nephrotic syndrome. With dasatinib dose reduction, urine protein level returned to the reference range. In order to determine the best genotype-guided therapy, the patient underwent pharmacogenomic testing, showing a homozygous CYP3A4 genotype *1/*1, associated with extensive metabolizer (EM) enzyme phenotype, typical for normal rates of drug metabolism for TKIs. However, this was inconsistent with nephrotic syndrome occurrence. A possible explanation would be CYP3A4 EM genotype coding a poor metabolizer enzyme phenotype, leading to the drug accumulation in the patient's blood. This transient phenoconversion can be explained by inflammation with elevated ESR during nephrotic syndrome. This case shows that a broader approach that recognizes genetic, clinical, and epigenomic factors is required for a quality decision on the personalized therapy regimen.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti



POVEZANOST RADA


Ustanove:
Medicinski fakultet, Rijeka,
Medicinski fakultet, Zagreb,
Klinički bolnički centar Zagreb,
Fakultet za dentalnu medicinu i zdravstvo, Osijek

Profili:

Avatar Url Dragan Primorac (autor)

doi

Citiraj ovu publikaciju

Rogulj, Inga Mandac; Matisic, Vid; Arsov, Borna; Boban, Luka; Juginovic, Alen; Molnar, Vilim; Primorac, Dragan
Dasatinib-induced nephrotic syndrome: a case of phenoconversion? // Croatian medical journal, 60 (2019), 3; 250-254 doi:10.3325/cmj.2019.60.250 (domaća recenzija, članak, znanstveni)
Rogulj, I., Matisic, V., Arsov, B., Boban, L., Juginovic, A., Molnar, V. & Primorac, D. (2019) Dasatinib-induced nephrotic syndrome: a case of phenoconversion?. Croatian medical journal, 60 (3), 250-254 doi:10.3325/cmj.2019.60.250.
@article{article, year = {2019}, pages = {250-254}, DOI = {10.3325/cmj.2019.60.250}, keywords = {Antineoplastic Agents/adverse effects, Antineoplastic Agents/metabolism, Cytochrome P-450 CYP3A/genetics, Dasatinib/adverse effects, Dasatinib/metabolism, Female Humans Imatinib Mesylate/therapeutic use, Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy, Nephrotic Syndrome/chemically induced, Pharmacogenomic Testing Phenotype Protein Kinase Inhibitors/adverse effects, Protein Kinase Inhibitors/metabolism, Pyrimidines/therapeutic use, }, journal = {Croatian medical journal}, doi = {10.3325/cmj.2019.60.250}, volume = {60}, number = {3}, issn = {0353-9504}, title = {Dasatinib-induced nephrotic syndrome: a case of phenoconversion?}, keyword = {Antineoplastic Agents/adverse effects, Antineoplastic Agents/metabolism, Cytochrome P-450 CYP3A/genetics, Dasatinib/adverse effects, Dasatinib/metabolism, Female Humans Imatinib Mesylate/therapeutic use, Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy, Nephrotic Syndrome/chemically induced, Pharmacogenomic Testing Phenotype Protein Kinase Inhibitors/adverse effects, Protein Kinase Inhibitors/metabolism, Pyrimidines/therapeutic use, } }
@article{article, year = {2019}, pages = {250-254}, DOI = {10.3325/cmj.2019.60.250}, keywords = {Antineoplastic Agents/adverse effects, Antineoplastic Agents/metabolism, Cytochrome P-450 CYP3A/genetics, Dasatinib/adverse effects, Dasatinib/metabolism, Female Humans Imatinib Mesylate/therapeutic use, Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy, Nephrotic Syndrome/chemically induced, Pharmacogenomic Testing Phenotype Protein Kinase Inhibitors/adverse effects, Protein Kinase Inhibitors/metabolism, Pyrimidines/therapeutic use, }, journal = {Croatian medical journal}, doi = {10.3325/cmj.2019.60.250}, volume = {60}, number = {3}, issn = {0353-9504}, title = {Dasatinib-induced nephrotic syndrome: a case of phenoconversion?}, keyword = {Antineoplastic Agents/adverse effects, Antineoplastic Agents/metabolism, Cytochrome P-450 CYP3A/genetics, Dasatinib/adverse effects, Dasatinib/metabolism, Female Humans Imatinib Mesylate/therapeutic use, Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy, Nephrotic Syndrome/chemically induced, Pharmacogenomic Testing Phenotype Protein Kinase Inhibitors/adverse effects, Protein Kinase Inhibitors/metabolism, Pyrimidines/therapeutic use, } }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Citati





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font